ClinicalTrials.gg
RecruitingNCT07158710Updated Sep 8, 2025

Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation

A Phase 1 interventional study of HSK42360 in Malignant Brain Tumors, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
159
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 179 studies in Brain Neoplasms with a site in China — 72 open to participants now, 84 under way, 6 of them phase 3. Brain Neoplasms · China.

Planned enrollment
38th of 142
159 · median 60
Started
2025
with 14 others
Phase 1
17 of 179
8 open now
Primary completion
2029-05
later than 76 of 83 live
Registered
149th of 179
by date

Among the 179 studies in Brain Neoplasms with a site in China, this one is the 38th largest by planned enrollment of the 142 interventional ones that give a count, is one of 15 that started in 2025, is one of 17 in phase 1, reaches primary completion later than 76 of the 83 other live ones, and was the 149th registered.

Brain Neoplasms

2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

72 of the 179 studies in Brain Neoplasms with a site in China are open now. Recruiting first, the newest first:

66 more — sign in →

All 72 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 425 Brain Neoplasms studies recruiting now, 286 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 179 studies in Brain Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK of HSK42360 when given orally in pediatric patients with active BRAF V600 mutation recurrent malignant brain tumors.

03

Conditions studied

  • Malignant Brain Tumors

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥6 and \<18 years.
  2. /Lansky Performance Status >60.
  3. ≥ 3 months.
  4. Patients with recurrent malignant brain tumors confirmed by histology or cytology, who have failed standard treatment (disease progression after treatment or intolerable treatment); patients who have previously received BRAF and/or MEK inhibitor therapy are allowed to be included in this study.
  5. Positive BRAF V600 mutation result confirmed prior to the administration of HSK42360.
  6. Patients will provide blood or tumor sample according to their own willingness.
  7. by RANO criteria.
  8. Patients with inactive CNS lesions, or patients treated with ≤5mg/day and without convulsion for ≥2 weeks.
  9. Adequate hematologic, hepatic, and renal function.
  10. Women of and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Patients with NF1 mutation.
  2. malignant tumor within 2 years, with the exception of cutaneous squamous cell carcinoma, cervical carcinoma in situ, papillary thyroid carcinoma, or other tumors with low .
  3. Uncontrollable pleural effusion, ascites, or pericardial effusion per protocol.
  4. Treatment with any of the following:

    Prior treatment with anti-tumor drug within 4 weeks or approximately 5 × t1/2 prior to the first dose of HSK42360, whichever is shorter; Prior treatment with nitrosourea or mitomycin C within 6 weeks prior to the first dose of HSK42360; Prior treatment with palliative radiotherapy or anti-tumor herbs within 2 weeks prior to the first dose of HSK42360; Prior treatment with radiotherapy, electric field therapy, or other anti-tumor therapies within 4 weeks prior to the first dose of HSK42360.

  5. Any unresolved toxicities from prior therapy greater than (CTCAE) grade 1 at the time of starting study treatment, with the exception of alopecia, dermal toxicity, and other toxicity considering no safety risks by investigator.
  6. Any disease which would preclude drug absorption, metabolism or pharmacokinetics, eg. active peptic ulcer or chronic gastroesophageal reflux disease.
  7. Patient who have or uncontrolled cardiac disease, include: ≥ 450 msec; any clinically significant arrhythmia; \< 50%; myocardial infarction, unstable angina, or class III/IV cardiac failure by the that occurred within 6 months prior to the first dose of HSK42360.
  8. Any thromboembolic events within 6 months prior to the first dose of HSK42360; any familial or aquired thrombophilia.
  9. Any unstable systemic disease, eg. severe metabolic disease: liver cirrhosis, renal failure, or uremia.
  10. Treatment with inhibitors/inducers for , or substrates of CYP3A4, CYP2C9, CYP2C8, OATP1B1, OATP1B3, OAT1, OAT3, P-gp or BCRP within 14 days or approximately 5 × t1/2 prior to the first dose of HSK42360, whichever is shorter.
  11. Patient with cognitive dysfunction, or history of mental illness, other uncontrolled comorbidities, alcohol dependence, hormone dependence or drug abuse.
  12. transplantation surgery within 3 months prior to the first dose of HSK42360; Allogeneic transplantation, or stem-cell Transplant surgery within 6 months prior to the first dose of HSK42360; Major surgery or significant traumatic injury occurring within 4 weeks prior to the first dose of HSK42360.
  13. Patient with a history of immunodeficiency, including positive, or other acquired/congenital immunodeficiency diseases.
  14. Patient with severe retinal abnormalities and uveitis.
  15. Patient with active or .
  16. Allergic to any HSK42360 active constituent or ingredients.
  17. Participate in other clinical trials within 4 weeks prior to the first dose of HSK42360.
  18. Positive pregnancy test, or breastfeeding.
  19. Any other circumstances that would, in the investigator's judgment, prevent the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
159 participants (estimated)

Study arms

  • Experimental
    Phase Ia: HSK42360 as monotherapy

    Phase 1a: dose escalation of HSK42360 as monotherapy at various dose levels

    Drug: HSK42360

  • Experimental
    Phase Ib: HSK42360 as monotherapy

    Phase 1b: dose expansion for HSK40118 as monotherapy at a dose determined during Phase 1a in patients with BRAF V600 recurrent mutation malignant brain tumors

    Drug: HSK42360

Interventions

06

What researchers measure

Primary outcomes

  1. MTD

    MTD determination: dose limiting toxicity (DLT) rate

    Time frame: Up to approximately 52 months

  2. DLTs

    Incidence of dose-limiting toxicities (DLTs) at Cycle1

    Time frame: Up to approximately 52 months

  3. AEs

    Rate and severity of adverse events of HSK42360 as monotherapy

    Time frame: Up to approximately 52 months

  4. RP2D

    RP2D determination: DLT, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary safety and anticancer activity data

    Time frame: Up to approximately 52 months

  5. Karnofsky/Lansky Performance Scale

    Change of the grade as a part of HSK43260 safety data

    Time frame: Up to approximately 52 months

Secondary outcomes

  1. Overall response rate (ORR)

    ORR, defined as the proportion of patients who experience a best response of confirmed CR or PR according to RANO

    Time frame: Up to approximately 52 months

  2. Disease control rate (DCR)

    DCR, defined as the proportion of patients who experience a best response of CR, PR, MR or stable disease (SD) according to RANO

    Time frame: Up to approximately 52 months

  3. Duration of response (DOR)

    DOR, defined as the time from first documented response of CR, PR or MR to the date of first documented progressive disease or death due to any cause, whichever occurs first

    Time frame: Up to approximately 52 months

  4. Progression free survival (PFS)

    PFS, defined as the time frocease or death due to any cause, whichever occurs first

    Time frame: Up to approximately 52 months

  5. Overall survival (OS)

    OS, defined as the time from the first dose of HSK42360 until the date of death due to any cause

    Time frame: Up to approximately 52 months

  6. Area under the curve (AUC)

    Time frame: Circle 1 (28days)

  7. maximum plasma concentration (Cmax)

    Time frame: Circle 1 (28days)

  8. half-life (t1/2)

    Time frame: Circle 1 (28days)

  9. Tmax(Time to maximum plasma concentration)

    Time frame: Circle 1 (28days)

07

Study locations

6 of 6 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for May 2029, 45 months after the start.

Of 205 phase 1 interventional studies under Brain Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 45 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2025
First posted
Sep 8, 2025
StartActual
Aug 15, 2025
Primary completionEst.
May 23, 2029
CompletionEst.
Dec 3, 2029
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07158710
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Aug 15, 2025
Primary completion
May 23, 2029 (estimated)
Completion
Dec 3, 2029 (estimated)
Last update
Sep 8, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK42360

Start the discussion